DNA methylation of RNA-binding protein for multiple splicing 2 functions as diagnosis biomarker in gastric cancer pathogenesis and its potential clinical significance

Ming Cheng, Xiaoan Zhan, Yi Xu, Saishan Wang, Hongcheng Zhang, Limin Fang, Jin Hao, Wei ChenBioengineered 2022 · DOI

TL;DR

This study reveals that DNA methylation of the RBPMS2 gene is a key driver of its downregulation in gastric cancer (GC), leading to increased tumor progression. The findings suggest that RBPMS2 DNA methylation levels can serve as a valuable diagnostic biomarker for GC, offering potential for improved early detection and prognosis.

What Problem Does This Paper Address?

Gastric cancer (GC) remains a significant global health challenge, characterized by high incidence and mortality rates, often due to late-stage diagnosis. While various biomarkers and screening methods exist, there's a persistent need for more convenient and accurate tools for early detection and prognosis. Previous research hinted at a link between RBPMS2 (RNA-binding protein for multiple splicing 2) and unfavorable GC outcomes, but the precise molecular mechanisms and its diagnostic potential, particularly concerning its DNA methylation, were unclear. This paper aims to elucidate the role of RBPMS2 DNA methylation in GC pathogenesis and assess its clinical significance as a diagnostic marker.

Methods

The researchers employed a multi-pronged approach to investigate RBPMS2 and its DNA methylation in GC:

  • Expression Analysis: Western blot and immunohistochemistry were used to assess RBPMS2 protein levels in GC specimens and cell lines. Quantitative real-time PCR (qRT-PCR) was utilized to measure RBPMS2 mRNA expression.
  • Functional Assays (In Vitro):
    • Cell Proliferation: CCK-8 assays were performed to quantify the impact of RBPMS2 overexpression or knockdown on GC cell growth.
  • Migration and Invasion: Transwell assays, with and without Matrigel, were used to evaluate the effects of RBPMS2 modulation on cell migration and invasion capabilities.
  • Apoptosis and Cell Cycle: Flow cytometry, including Annexin V/PI staining and TUNEL assays, was employed to assess apoptosis rates and cell cycle distribution.
  • DNA Methylation Analysis:
    • CpG Island Prediction: MethPrimer software was used to identify CpG islands in the RBPMS2 promoter region.
  • Methylation Status: Methylation-Specific PCR (MSP) was conducted to determine the methylation status of the RBPMS2 promoter in GC tissues versus normal tissues.
  • Methylated DNA Immunoprecipitation (MeDIP): This technique was used to assess the enrichment of 5-methylcytosine (5mC) at the RBPMS2 promoter.
  • DNA Methylation Inhibitors: The study utilized 5-aza-2'-deoxycytidine (5-aza-DC) and RG108, known DNA methylation inhibitors, to investigate their effects on RBPMS2 expression and GC cell behavior.
  • In Vivo Studies: A xenograft mouse model was established using GC cells. Tumor growth, inflammatory cell infiltration (H&E staining), proliferation (Ki-67 staining), and apoptosis (TUNEL staining) were assessed in response to RBPMS2 manipulation and 5-aza-DC treatment.
  • Statistical Analysis: Standard statistical methods, including t-tests, ANOVA, and ROC curve analysis, were applied to evaluate the significance of the findings.

Datasets

The study utilized:

  • Human GC Tissues: 80 GC tissues and matched adjacent non-tumor tissues were collected from patients at Zhejiang Jinhua Guangfu Tumor Hospital.
  • GC Cell Lines: MGC-803, AGS, SNU-1, HGC-27, KATO III, and the normal gastric epithelial GES-1 cell line were used.
  • Publicly Available Data: The GEPIA website (http://gepia.cancer-pku.cn/) was used to analyze gene expression data from TCGA and GTEx databases for SCNN1B, NFE2L3, CLDN2, and RBPMS2 in GC tissues.

Key Insights and Ideas

  • RBPMS2 as a Tumor Suppressor: The research strongly suggests that RBPMS2 acts as a tumor suppressor in GC. Its overexpression inhibits cell proliferation, migration, and invasion, while promoting apoptosis. Conversely, silencing RBPMS2 has the opposite effect, promoting these aggressive behaviors.
  • Epigenetic Silencing via DNA Methylation: The core finding is that DNA methylation of the RBPMS2 promoter is the primary mechanism responsible for its downregulation in GC. This epigenetic silencing appears to be the driving force behind RBPMS2's reduced expression and subsequent promotion of tumor progression.
  • Diagnostic Potential of RBPMS2 Methylation: The study establishes a significant correlation between RBPMS2 DNA methylation levels and key GC pathological features, including tumor invasion depth, Borrmann classification, and TNM stage. This strong association highlights its potential as a valuable diagnostic biomarker.
  • Reversal of Malignant Phenotypes: Treatment with DNA methylation inhibitors (5-aza-DC and RG108) could partially reverse the suppressive effects of RBPMS2 silencing, restoring RBPMS2 expression and mitigating aggressive GC cell behaviors. This underscores the critical role of DNA methylation in GC progression.

Key Results

  • RBPMS2 Downregulation: RBPMS2 expression was significantly reduced in GC specimens compared to normal tissues, and this low expression was associated with poorer patient survival.
  • Diagnostic Accuracy: The ROC curve analysis indicated that RBPMS2 could serve as a diagnostic biomarker for GC with a sensitivity of 65.89% and specificity of 81.82% (Area under ROC = 0.7778).
  • Methylation Correlation: RBPMS2 promoter methylation was significantly increased in GC tissues. This methylation was strongly associated with tumor invasion depth (P=0.000), Borrmann classification (P<0.001), and TNM stage (P=0.009*).
  • Inhibitor Efficacy: 5-aza-DC treatment partially restored RBPMS2 expression in silenced cells and significantly inhibited tumor growth, proliferation, and invasion while promoting apoptosis in vivo.

Limitations and Future Work

  • Partial Reversal: While DNA methylation inhibitors showed promising results, they only partially reversed the effects of RBPMS2 suppression. This suggests that other regulatory mechanisms might also be involved in GC progression.
  • In Vivo Model Specificity: The in vivo studies were conducted using a xenograft model, which, while informative, may not fully recapitulate the complex tumor microenvironment of human GC.
  • Further Validation: The authors acknowledge that the diagnostic and prognostic value of RBPMS2 DNA methylation needs further investigation in larger, diverse patient cohorts. They suggest that this epigenetic marker could be a promising candidate for future clinical applications.
  • Mechanism of Methylation: While the study identifies RBPMS2 promoter methylation as a key event, further research could delve deeper into the specific DNMTs involved and the interplay with other regulatory factors like ESRP1.

Summary updated

Abstract

Higher methylation levels of RNA-binding protein for multiple splicing 2 (RBPMS2) was reported to be related with unfavorable outcome in gastric cancer (GC). However, molecular function and diagnostic significance of DNA methylation of RBPMS2 remains indistinct. Here we aimed to whether DNA methylation of RBPMS2 acts as a diagnosis biomarker in GC pathogenesis and its potential clinical significance. Western blot and immunochemistry assays were carried out to explore the level of RBPMS2. GC malignancy behaviors were determined by cell counting kit-8, Transwell, flow cytometry analysis and terminal-deoxynucleoitidyl transferase mediated nick end labeling staining. The inflammatory cell infiltration in xenograft model was observed by hematoxylin and eosin staining. CpG Islands was predicted by MethPrimer and the DNA methylation of RBPMS2 was evaluated by methylation-specific polymerase chain reaction. The results showed that RBPMS2 was downregulated in GC specimens. Poor survival rates were associated with low RBPMS2 expression. Overexpression of RBPMS2 inhibited GC growth while facilitated apoptosis in GC cells. In addition, level of DNA methylation of RBPMS2 in GC tissues was increased and DNA methylation of RBPMS2 was strongly associated with tumor invasion, Borrmann classification and TNM stage. We also observed that DNA methylation inhibitors counteracted the role of RBPMS2 in restraining GC development and tumorigenesis. To sum, our data demonstrated that DNA methylation of RBPMS2 was responsible for its downregulation in GC and promoted tumor progression, indicating DNA methylation of RBPMS2 might serve as a valuable potential parameter in GC pathogenesis.
BibTeX
@inproceedings{cheng2022dna,
  author = {Ming Cheng and Xiaoan Zhan and Yi Xu and Saishan Wang and Hongcheng Zhang and Limin Fang and Jin Hao and Wei Chen},
  title = {{DNA methylation of RNA-binding protein for multiple splicing 2 functions as diagnosis biomarker in gastric cancer pathogenesis and its potential clinical significance}},
  booktitle = {Bioengineered},
  year = {2022},
  doi = {10.1080/21655979.2022.2032965},
}
Figure